Targeting the PI3K–Akt pathway in kidney cancer

References

• Weiss RH, Lin P-Y. Kidney cancer: identification of novel targets for therapy. Kidney Int.69, 224–232 (2006).
   PubMedGoogle Scholar
• Tuma RS. Three molecularly targeted drugs tested in kidney cancer clinical trials. J. Natl Cancer Inst.96, 1270–1271 (2004).
   Google Scholar
• Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer101, 1545–1551 (2004).
   PubMed Web of Science ®Google Scholar
• Vuky J, Motzer RJ. Cytokine therapy in renal cell cancer. Urol. Oncol.5, 249–257 (2000).
   Google Scholar
• Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J. Sci. Am.3(Suppl. 1), S70–S72 (1997).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer5, 65–72 (2005).
   PubMed Web of Science ®Google Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal.14, 381–395 (2002).
   PubMed Web of Science ®Google Scholar
• Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT – a major therapeutic target. Biochim. Biophys. Acta1697, 3–16 (2004).
   PubMed Web of Science ®Google Scholar
• Horiguchi A, Oya M, Uchida A, Marumo K, Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J. Urol.169, 710–713 (2003).
   PubMed Web of Science ®Google Scholar
• Sourbier C, Lindner V, Lang H et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res.66, 5130–5142 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JS, Kim HS, Kim YB, Lee MC, Park CS. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J. Surg. Oncol.84, 166–172 (2003).
   PubMed Web of Science ®Google Scholar
• Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol.16, 928–933 (2005).
   PubMed Web of Science ®Google Scholar
• Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer99, 53–57 (2002).
   PubMed Web of Science ®Google Scholar
• Alimov A, Li C, Gizatullin R et al. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res.19, 3841–3846 (1999).
   PubMedGoogle Scholar
• Sukosd F, Digon B, Fischer J, Pietsch T, Kovacs G. Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma. Cancer Genet. Cytogenet.128, 161–163 (2001).
   PubMedGoogle Scholar
• Figlin RA, Seligson D, Wu H et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J. Clin. Oncol.23(16 Suppl.) (2005) (Abstract 4539).
   PubMedGoogle Scholar
• Eng C. PTEN: one gene, many syndromes. Hum. Mutat.22, 183–198 (2003).
   PubMed Web of Science ®Google Scholar
• Osaki M, Oshimura M, Ito H. PI3K–Akt pathway: its functions and alterations in human cancer. Apoptosis9, 667–676 (2004).
   PubMed Web of Science ®Google Scholar
• Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta1436, 127–150 (1998).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J. Immunother.27, 259–264 (2004).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-α or interferon-α plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res.10, 2584–2586 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295, 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Flaherty KT. Sorafenib in renal cell carcinoma. Clin. Cancer Res.13, S747–S752 (2007).
   Google Scholar
• Wiesinger D, Gubler HU, Haefliger W, Hauser D. Antiinflammatory activity of the new mould metabolite 11-desacetoxy-wortmannin and of some of its derivatives. Experientia30, 135–136 (1974).
   PubMedGoogle Scholar
• Wymann MP, Bulgarelli-Leva G, Zvelebil MJ et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell Biol.16, 1722–1733 (1996).
   PubMed Web of Science ®Google Scholar
• Wetzker R, Rommel C. Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr. Pharm. Des.10, 1915–1922 (2004).
   PubMedGoogle Scholar
• Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J.351, 95–105 (2000).
   PubMed Web of Science ®Google Scholar
• Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res.60, 5451–5455 (2000).
   PubMed Web of Science ®Google Scholar
• Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits PKB/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res.7, 3269–3275 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Cerniglia GJ, Mick R et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int. J. Radiat. Oncol. Biol. Phys.56, 846–853 (2003).
   PubMed Web of Science ®Google Scholar
• Yu K, Lucas J, Zhu T et al. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol. Ther.4, 538–545 (2005).
   PubMed Web of Science ®Google Scholar
• Breitenlechner CB, Wegge T, Berillon L et al. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem.47, 1375–1390 (2004).
   PubMed Web of Science ®Google Scholar
• Chijiwa T, Mishima A, Hagiwara M et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem.265, 5267–5272 (1990).
   PubMed Web of Science ®Google Scholar
• Redaelli C, Granucci F, De Gioia L, Cipolla L. Synthesis and biological activity of Akt/PI3K inhibitors. Mini. Rev. Med. Chem.6, 1127–1136 (2006).
   PubMedGoogle Scholar
• Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis PA. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol. Cancer Ther.5, 713–722 (2006).
   PubMed Web of Science ®Google Scholar
• Maffucci T, Piccolo E, Cumashi A et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res.65, 8339–8349 (2005).
   PubMed Web of Science ®Google Scholar
• Piccolo E, Vignati S, Maffucci T et al. Inositol pentakisphosphate promotes apoptosis through the PI3-K/Akt pathway. Oncogene23, 1754–1765 (2004).
   Google Scholar
• Claerhout S, Decraene D, Van Laethem A, Van Kelst S, Agostinis P, Garmyn M. AKT delays the early-activated apoptotic pathway in UVB-irradiated keratinocytes via BAD translocation. J. Invest Dermatol.127, 429–438 (2007).
   PubMedGoogle Scholar
• Liou JY, Ghelani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3ε. Cancer Res.67, 3185–3191 (2007).
   Google Scholar
• Kubo S, Doe I, Kurokawa Y, Nishikawa H, Kawabata A. Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. Toxicology232, 138–146 (2007).
   PubMed Web of Science ®Google Scholar
• Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog. Cell Cycle Res.1, 53–71 (1995).
   PubMedGoogle Scholar
• Lin PY, Fosmire SP, Park SH et al. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol. Cancer6, 16 (2007).
   PubMedGoogle Scholar
• Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int.63, 917–926 (2003).
   PubMedGoogle Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Proc. Ann. Meet. Am. Soc. Clin. Oncol.24(Suppl.) S18 (2006).
   Google Scholar
• Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage-induced apoptosis through inhibition of p21 translation. Cell120, 747–759 (2005).
   PubMed Web of Science ®Google Scholar
• Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell4, 425–429 (2003).
   PubMedGoogle Scholar